ClinicalTrials.gg
Not yet recruitingNCT07652931AHEADUpdated Nov 10, 2026

Using Artificial Intelligence to Detect Early Signs of Alzheimer's Disease in People With Memory Concerns

An interventional study of High-frequency Transcranial Magnetic Stimulation (TMS) and Digital Cognitive Training in Subjective Cognitive Decline, Alzheimer Disease and Mild Cognitive Impairment, sponsored by IRCCS San Raffaele. Not yet recruiting at 1 site in Italy. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2026-11-10.

Sponsored by IRCCS San Raffaele · Not applicable, Interventional, and Other

How we know

Updated Nov 10, 2026Start date movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
300
Allocation
Not applicable
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies in Alzheimer Disease by IRCCS San Raffaele — 8 open to participants now, 8 under way, none of them phase 3. Alzheimer Disease · IRCCS San Raffaele.

Started
2026
with 3 others
No phase
4 of 10
4 open now
Registered
7th of 10
by date

Among the 10 studies in Alzheimer Disease by IRCCS San Raffaele, this one is one of 4 that started in 2026, is one of 4 with no phase, and was the 7th registered.

Alzheimer Disease

3,972 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

8 of the 10 studies in Alzheimer Disease by IRCCS San Raffaele are open now, in 1 country. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 8 open studies →

Where they have run

Who these studies take

Of the 645 Alzheimer Disease studies recruiting now, 282 (44%) set no upper age limit and 57 (9%) stop at 75 or younger; 34 take children under 18; 288 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Alzheimer Disease by IRCCS San Raffaele, or all of them as a file.
02

Study summary

AHEAD is a prospective, longitudinal, risk-stratified single-arm interventional study enrolling 300 patients with Subjective Cognitive Decline (SCD) at IRCCS San Raffaele Hospital, Milan, Italy.

The study uses artificial intelligence (AI) to integrate multimodal data - including MRI, EEG, Optical Coherence Tomography (OCT), neuropsychological assessments, and plasma biomarkers - to identify individuals with underlying Alzheimer's disease (AD) biology and predict cognitive progression.

Only participants found to be AD plasma biomarker positive (SCD+) undergo longitudinal follow-up at 12 and 24 months. Participants classified as high risk additionally receive a 6-month personalized multidisciplinary intervention combining high-frequency transcranial magnetic stimulation (TMS), digital cognitive training, structured physical exercise, and targeted management of modifiable vascular and behavioral risk factors.

Read the detailed description

Subjective Cognitive Decline (SCD) refers to the self-perception of worsening cognitive abilities despite normal performance on standardized neuropsychological testing. It affects approximately 10% of the general population and 20-35% of patients attending memory clinics. Although the majority of individuals with SCD do not progress to clinical forms of Alzheimer's disease (AD), they show a higher prevalence of AD-related pathological biomarkers compared with individuals without subjective cognitive complaints, with rates of cognitive decline estimated at approximately 20% per 1,000 person-years in memory clinic patients.

Plasma biomarkers for AD represent minimally invasive and easily accessible diagnostic tools; however, their large-scale implementation in the broad SCD population is neither economically nor ethically sustainable because of costs, the risk of overdiagnosis, and the associated psychological burden. Artificial intelligence (AI) may represent a transformative tool for addressing the complexity of SCD management. By integrating multimodal data including cognitive assessments, MRI, EEG, and OCT, AI may help identify those individuals with SCD most likely to benefit from further diagnostic investigations, including plasma biomarker assessment.

At baseline (T0), all participants undergo a minimum assessment dataset including clinical evaluation, standard neuropsychological assessment, structural MRI, and blood sampling. A subset additionally undergoes a comprehensive risk assessment, extended neuropsychological evaluation including digital cognitive testing and the Preclinical Alzheimer Cognitive Composite (PACC), resting-state EEG, and retinal imaging through Optical Coherence Tomography (OCT).

Only patients found to be AD plasma biomarker positive (SCD+) undergo longitudinal follow-up visits at 12 months (M12) and 24 months (M24), including clinical evaluation, neuropsychological assessments, and blood sampling to monitor cognitive and biological progression.

Participants stratified as high risk - defined as plasma p-tau217 greater than 0.1325 pg/mL, and/or APOE epsilon4 carrier, and/or elevated CAIDE Dementia Risk Score - enter a 6-month single-arm multidisciplinary intervention comprising: (1) targeted management of modifiable vascular and behavioral risk factors with monthly remote follow-up; (2) high-frequency TMS during the first 4 weeks (2-3 sessions per week); (3) home-based digital cognitive training, 2 sessions per week of 30 minutes each over 5 months; (4) structured physical exercise (walking, cycling, resistance training), 2 sessions per week of 30 minutes each.

A retrospective SCD cohort (rSCD), comprising patients who underwent the minimum assessment dataset within one year prior to enrollment and were found to be AD plasma biomarker positive, undergoes follow-up at M12 and M24 according to the same longitudinal protocol, with the intervention starting at M12.

AI models will integrate multimodal baseline data using machine learning (logistic regression, random forest), deep learning (CNNs for MRI/OCT, RNNs/Transformers for EEG), and survival analysis (Cox proportional hazards, DeepSurv). All models will be validated using k-fold cross-validation with performance metrics including AUC, sensitivity, specificity, balanced accuracy, and positive and negative predictive values.

03

Conditions studied

  • Subjective Cognitive Decline
  • Alzheimer Disease
  • Mild Cognitive Impairment
  • Cognitive Decline

Keywords

  • Subjective Cognitive Decline
  • Alzheimer's disease
  • Artificial Intelligence
  • Transcranial Magnetic Stimulation
  • Plasma biomarkers
  • p-tau217
  • MRI
  • EEG
  • Optical Coherence Tomography
  • Cognitive Training
  • Physical Exercise
  • Brain Health
  • APOE
  • Machine Learning
  • Deep Learning
04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Diagnosis of Subjective Cognitive Decline (SCD) according to international diagnostic criteria (Jessen et al., 2014).
  2. Self-experienced persistent decline in cognitive capacity in comparison with a previously normal status and unrelated to an acute event.
  3. Normal age-, gender-, and education-adjusted performance on standardized cognitive tests used to classify mild cognitive impairment (MCI) or prodromal AD.
  4. Age greater than or equal to 40 years.
  5. Native Italian Speaker.
  6. Stable pharmacological treatment for at least 4 weeks prior to enrollment.
  7. Provision of oral and written to study participation.

Exclusion criteria

Exclusion Criteria:

  1. Presence of MCI, prodromal AD, or dementia.
  2. Any major systemic, psychiatric, or neurological disturbance.
  3. Medical conditions or substance abuse that could interfere with cognition.
  4. Pacemaker and/or other implanted neurostimulation devices in the head/neck district.
  5. to undergoing MRI examination.
  6. Brain damage at routine MRI, including extensive cerebrovascular disorders.
  7. Traumatic or surgical wounds that could determine a risk of infection at the site of non-invasive stimulation.
  8. Scalp alterations that could determine the spread of excessive current from the device.
  9. Known history of epilepsy (due to small risk of seizure induction from rTMS in epileptic patients).
  10. Denial of oral and written to study participation.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
300 participants (estimated)

Study arms

  • Experimental
    SCD Participants

    All 300 SCD participants undergo baseline multimodal assessment. Those found to be AD plasma biomarker positive (SCD+) undergo longitudinal follow-up at M12 and M24. Those classified as high risk (plasma p-tau217 greater than 0.1325 pg/mL, and/or APOE epsilon4 carrier, and/or elevated CAIDE Dementia Risk Score) additionally receive a 6-month multidisciplinary personalized intervention combining high-frequency TMS, digital cognitive training, structured physical exercise, and targeted vascular and behavioral risk factor management.

    Device: High-frequency Transcranial Magnetic Stimulation (TMS) · Behavioral: Digital Cognitive Training · Behavioral: Structured Physical Exercise · Other: Management of Modifiable Vascular and Behavioral Risk Factors

Interventions

  • DeviceHigh-frequency Transcranial Magnetic Stimulation (TMS)

    High-frequency repetitive TMS (rTMS) delivered according to an intensive protocol during the first 4 weeks of the intervention period (2-3 sessions per week). Applied to brain regions associated with cognitive function to optimize brain health and reduce risk of cognitive decline. Administered by trained professionals following international safety guidelines (Rossi et al., 2009).

  • BehavioralDigital Cognitive Training

    Home-based cognitive training delivered via digital platform over 5 months: 2 sessions per week of 30 minutes each. Targets perceived cognitive deficits and related domains (memory, executive functions, attention, visuospatial abilities, language) with progressive adaptation to individual performance level. Compliance monitored via dedicated applications and/or activity diaries. Monthly remote meetings with neuropsychologists to monitor progress.

  • BehavioralStructured Physical Exercise

    Home-based structured physical exercise program over 5 months: 2 sessions per week of 30 minutes each. Activities include walking, cycling, and global resistance training. An in-person familiarization session is conducted before program start. Monthly remote meetings with physiotherapists to monitor progress and adapt the program. Compliance remotely monitored via dedicated applications and/or activity diaries.

  • OtherManagement of Modifiable Vascular and Behavioral Risk Factors

    Personalized pharmacological and non-pharmacological interventions targeting modifiable vascular and behavioral risk factors including blood pressure, cholesterol, BMI, physical inactivity, dietary habits, sleep quality, and social isolation. Monthly remote follow-up visits over 6 months to monitor treatment adherence and optimize risk factor control.

06

What researchers measure

Primary outcomes

  1. Diagnostic accuracy of AI models in identifying AD biomarker-positive SCD subjects (AUC)

    Area under the ROC curve (AUC), sensitivity, and specificity of AI models in discriminating between plasma AD biomarker-positive and biomarker-negative SCD subjects, assessed at study entry.

    Time frame: Baseline (study entry)

Secondary outcomes

  1. Predictive accuracy of AI models for cognitive progression (AUC)

    Area under the ROC curve (AUC), sensitivity, and specificity of AI models in discriminating between SCD progressors and non-progressors (conversion to Mild Cognitive Impairment or dementia) over a 24-month follow-up period.

    Time frame: Baseline, 12 months (M12), and 24 months (M24)

Other outcomes

  1. Change in Preclinical Alzheimer Cognitive Composite (PACC) score

    Preclinical Alzheimer Cognitive Composite (PACC) score assessed before and after the intervention. Higher scores indicate better cognitive performance. Primary outcome is maintenance of a stable PACC score after the intervention.

    Time frame: Before and after the 6-month intervention (Baseline to Month 6 , or Month12 to Month 18 for rSCD cohort)

  2. Change in self-perceived quality of life (EQ-5D-3L)

    Self-perceived quality of life measured by the EQ-5D-3L patient-reported instrument. Higher scores indicate better quality of life.

    Time frame: Before and after the 6-month intervention (Baseline to Month 6 , or Month12 to Month 18 for rSCD cohort)

  3. Change in 6-minute walking test distance

    Distance in meters walked in 6 minutes. An increase in distance indicates improved physical performance.

    Time frame: Before and after the 6-month intervention (Baseline to Month 6 , or Month12 to Month 18 for rSCD cohort)

  4. Change in functional upper limb strength

    Global upper limb strength changes assessed via standardized functional strength tests before and after the intervention.

    Time frame: Before and after the 6-month intervention (Baseline to Month 6 , or Month12 to Month 18 for rSCD cohort)

  5. Change in functional lower limb strength

    Global lower limb strength changes assessed via standardized functional strength tests before and after the intervention.

    Time frame: Before and after the 6-month intervention (Baseline to Month 6 , or Month12 to Month 18 for rSCD cohort)

  6. Change in heart rate (bpm)

    Change in heart rate (bpm), measured before and after the intervention program.

    Time frame: Before and after the 6-month intervention (Baseline to Month 6 , or Month12 to Month 18 for rSCD cohort)

  7. Change in systolic blood pressure (mmHg)

    Change in systolic blood pressure (mmHg), measured before and after the intervention program.

    Time frame: Before and after the 6-month intervention (Baseline to Month 6 , or Month12 to Month 18 for rSCD cohort)

  8. Change in diastolic blood pressure (mmHg)

    Change in diastolic blood pressure (mmHg), measured before and after the intervention program.

    Time frame: Before and after the 6-month intervention (Baseline to Month 6 , or Month12 to Month 18 for rSCD cohort)

  9. Change in Borg perceived exertion scale

    Change in Borg perceived exertion scale measured before and after the intervention program.

    Time frame: Before and after the 6-month intervention (Baseline to Month 6 , or Month12 to Month 18 for rSCD cohort)

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2026; primary completion for Aug 2028, 20 months later.

Of 887 non-industry interventional studies with no phase under Alzheimer Disease, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 51. This study's planned 20 months is below that.

Counting every sponsor, half of 964 studies reached it within 29 months; a quarter within 15 and three quarters within 51.

Start moved once since we started tracking on Sep 25, 2026: Aug 2026 → Dec 2026, on Nov 10, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 8, 2026
First posted
Jun 17, 2026
StartEst.
Dec 1, 2026was Aug 2026
Primary completionEst.
Aug 1, 2028
CompletionEst.
Aug 1, 2029
Last update
Nov 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Aug 1, 2026→Dec 1, 2026
Nov 10, 2026
Show all 1 update
  1. Nov 10, 2026
    Start date Aug 1, 2026→Dec 1, 2026

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07652931
Lead sponsor
IRCCS San Raffaele
Responsible party
Prof. Massimo Filippi (Prof, MD, IRCCS San Raffaele) — Principal investigator
First posted
Jun 17, 2026
Start date
Dec 1, 2026 (estimated)
Primary completion
Aug 1, 2028 (estimated)
Completion
Aug 1, 2029 (estimated)
Last update
Nov 10, 2026

Study contacts

Federica FA Agosta, MD
Contact
agosta.federica@hsr.it
0226433051
Elisa EC Canu, PhD
Contact
canu.elisa@hsr.it
0226433033
Massimo Filippi, Prof
principal investigator · IRCCS San Raffaele

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion